Equities

Nanjing King-friend Biochemical Pharmaceutical Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Nanjing King-friend Biochemical Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)9.83
  • Today's Change-0.04 / -0.41%
  • Shares traded9.59m
  • 1 Year change-31.26%
  • Beta1.2878
Data delayed at least 15 minutes, as of Feb 13 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Nanjing King-friend Biochemical Pharmaceutical Co Ltd is a China-based company mainly engaged in the research and development, production, and sales of drugs. The Company's main products include cardiovascular, neurological, anesthetic, anti-tumor preparations, surgical auxiliary and other high-value-added sterile injections. The Company's main businesses include: sterile injection business, heparin API business, pharmaceutical contract research and development and production organization (CDMO) business, and biopharmaceutical innovation business.

  • Revenue in CNY (TTM)3.76bn
  • Net income in CNY649.83m
  • Incorporated2000
  • Employees1.36k
  • Location
    Nanjing King-friend Biochemical Pharmaceutical Co LtdNo. 16 Xuefu RoadHigh-tech Industrial Development ZoneNANJING 210061ChinaCHN
  • Phone+86 2 586990789
  • Fax+86 2 586990701
  • Websitehttps://www.nkf-pharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Shanghai Haoyuan Chemexpress Co Ltd2.71bn294.90m14.95bn3.58k50.514.80--5.521.401.4012.8514.670.5041.103.98757,880.405.375.947.327.8048.9345.0910.6611.741.467.540.410216.9520.7540.8958.1722.3871.42--
Zhejiang Medicine Co Ltd8.96bn1.24bn15.41bn5.82k12.391.39--1.721.291.299.3111.500.64992.765.651,540,449.008.195.3110.156.9339.4736.9712.607.682.01--0.078430.9120.295.88170.1127.623.74-18.03
Zhejiang Jiuzhou Pharmaceutical Co Ltd5.36bn722.87m15.61bn5.00k21.631.78--2.910.81130.81136.079.840.4931.974.841,070,948.006.659.237.9112.1934.6533.7813.5015.642.42--0.015239.55-6.5720.67-41.3420.5822.648.45
China Resources Jingzhng Phrmctcl Co Ltd4.40bn837.30m15.85bn4.18k18.884.18--3.601.321.326.945.980.67553.5311.301,051,350.0014.1211.4523.3116.7260.9664.0420.9118.231.33--0.034893.25-2.5912.619.6711.2030.6736.85
Nanjing King-Frind Bchmcl Phrmctcl C Ltd3.76bn649.83m15.88bn1.36k24.102.35--4.220.40790.40792.354.180.38120.63223.822,765,677.006.598.388.9912.0341.1244.9517.2819.721.35--0.264423.22-0.19849.70536.096.4334.44-6.04
Guobang Pharma Ltd5.94bn872.95m15.96bn4.00k18.191.93--2.691.571.5710.6814.800.56033.067.041,484,531.008.209.5210.3312.4724.6727.1014.6414.912.30--0.103824.7610.129.1527.6119.94-7.08--
Tonghua Dongbao Pharmaceutical Co Ltd2.74bn1.23bn17.04bn3.41k13.872.39--6.220.62710.62711.403.640.35891.055.11803,924.6015.8414.8917.0815.6871.0578.8644.1535.263.49--0.098850.60-34.66-6.27-103.66--14.174.56
Data as of Feb 13 2026. Currency figures normalised to Nanjing King-friend Biochemical Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

7.76%Per cent of shares held by top holders
HolderShares% Held
E Fund Management Co., Ltd.as of 30 Jun 202547.87m2.97%
Bank of Communications Schroder Fund Management Co., Ltd.as of 30 Jun 202534.27m2.12%
China Merchants Fund Management Co., Ltd.as of 30 Jun 202511.59m0.72%
China Southern Asset Management Co., Ltd.as of 30 Jun 20257.18m0.45%
Rongtong Fund Management Co., Ltd.as of 30 Jun 20257.00m0.43%
Franklin Templeton Sealand Fund Management Co., Ltd.as of 30 Jun 20254.81m0.30%
Zhong Ou Asset Management Co., Ltdas of 30 Jun 20254.32m0.27%
The Vanguard Group, Inc.as of 31 Dec 20253.90m0.24%
Cinda Fund Management Co. Ltd.as of 30 Jun 20252.45m0.15%
Aegon-Industrial Fund Management Co., Ltd.as of 30 Jun 20251.90m0.12%
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.